HCMHUTCHMED (China) Limited

$3B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$162M+6.4% YoY

Gross Profit

-$28M-17.4% margin

Operating Income

-$8M-5.0% margin

Net Income

$6M3.7% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$16M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$502M

Stockholders' Equity

$760M

Cash & Equivalents

$154M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$162M	$153M	+6.4%
Gross Profit	-$28M	-$14M	-98.6%
Operating Income	-$8M	-$47M	+82.6%
Net Income	$6M	-$34M	+117.6%

HCM Q4 2024 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena